Hypertension
Conditions
Keywords
hypertension, angiotensin receptor blockers, peroxisome proliferator activated receptor gamma
Brief summary
The purpose of this study is to determine whether losartan metabolites are effective in inducing PPARγ target genes in monocytes in losartan-treated patients.
Detailed description
The losartan metabolite EXP3179 potently induces the activity of the peroxisome proliferator-activated receptor γ (PPAR-γ) as a partial agonist in vitro. PPAR-γ is a nuclear hormone receptor and functions as a regulator of lipid- and glucose metabolism. PPAR-γ ligands improve insulin sensitivity and glucose tolerance, and reduce cardiovascular morbidity and mortality in diabetic patients. Angiotensin II receptor 1-blocking and PPAR-γ-activating properties of losartan metabolites in patients would markedly improve the pharmacological profile of losartan by combining anti-hypertensive and highly beneficial metabolic actions. We developed the following hypothesis: 1. Hypertensive patients chronically treated with losartan exhibit sufficient plasma levels of EXP3179 to activate PPARγ. 2. PPARγ target genes are induced in monocytes from losartan-treated patients.
Interventions
DRUGlosartan
Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
Sponsors
Charite University, Berlin, Germany
Merck Sharp & Dohme LLC
German Heart Institute
Study design
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age: 19-80 * Sex: male or female * Prior diagnosis of treated hypertension * Treatment with losartan 100mg/daily during at least the past 2 months (n=20/ case); * or: no prior angiotensin receptor 1-blocker treatment during the last 2 months (n=10/ control).
Exclusion criteria
* Non-steroidal anti-inflammatory drugs (exception: Acetyl salicylic acid) for the past 21 days (due to structural homologies to glitazones, and activating effects on PPARγ) * Therapy with glitazones for the past 21 days.
Countries
Germany
Contacts
Primary ContactEckart Fleck, Prof
Backup ContactPhilipp Stawowy, Dr
Outcome results
None listed